The influence of Telmisartan on insulin resistance and fatty liver in patients suffer from hypertension: A phase IV, randomised controlled trial.
Phase of Trial: Phase IV
Latest Information Update: 26 Apr 2013
At a glance
- Drugs Telmisartan (Primary)
- Indications Fatty liver; Hypertension; Insulin resistance
- Focus Therapeutic Use
- Acronyms InReTel
- 10 Jun 2017 Biomarkers information updated
- 26 Apr 2013 Status changed from recruiting to completed as reported by European Clinical Trials Database.
- 15 Mar 2012 Planned end date changed from 30 Sep 2011 to 11 Jun 2013 as reported by European Clinical Trials Database.